Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.
Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.
Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.
ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.
ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.
Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.
JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.
Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.
Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.
Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.
